Fliser D, Stefanski A, Franek E, Fode P, Gudarzi A, Ritz E
Department of Internal Medicine, Ruperto-Carola University, Heidelberg, Germany.
Eur J Clin Invest. 1997 Jul;27(7):629-33. doi: 10.1046/j.1365-2362.1997.1520699.x.
Administration of active vitamin D (calcitriol) improves insulin sensitivity in uraemic patients. These patients have subnormal plasma calcitriol concentrations in parallel with increased intact parathyroid hormone (PTH) concentrations. It is therefore unclear whether the improvement in insulin sensitivity results from a direct effect of calcitriol or from amelioration of secondary hyperparathyroidism. So far, no evidence has been presented that insulin sensitivity is specifically affected by calcitriol in healthy subjects. We investigated the effect of (supra)therapeutic doses of calcitriol on insulin sensitivity in healthy volunteers. In a double-blind parallel group design, 18 healthy male subjects received in random order either placebo or 1.5 micrograms of calcitriol per day by mouth for 7 days. Insulin-mediated glucose uptake, i.e. insulin sensitivity, was assessed using the euglycaemic clamp technique. Mean glucose disposal rate, i.e. M-value, was not significantly affected by placebo or calcitriol treatment (placebo: 7.1 +/- 1.3 mg kg-1 min-1 before and 7.2 +/- 1.5 mg kg-1 min-1 after treatment; calcitriol 7.0 +/- 1.4 mg kg-1 min-1 and 7.2 +/- 1.4 mg kg-1 min-1). There were no significant changes in mean plasma glucose, insulin, phosphate, bicarbonate and ionized calcium concentrations after administration of placebo or calcitriol. Furthermore, platelet intracellular calcium concentration (assessed by fluorescence spectroscopy) and mean arterial blood pressure (24 h ambulatory measurement) did not change with placebo and calcitriol treatment. On the other hand, mean intact PTH concentration decreased significantly (P < 0.01) with calcitriol treatment, but not with placebo. In addition, mean 24 h urinary calcium excretion increased significantly (P < 0.05) with calcitriol administration but was unchanged with placebo. Administration of (supra)physiological doses of calcitriol has no effect on insulin sensitivity in healthy subjects, despite a significant decrease in PTH concentrations. These observations are compatible with the notion that the effect of calcitriol on insulin sensitivity is present only in uraemic calcitriol-depleted patients.
给予活性维生素D(骨化三醇)可改善尿毒症患者的胰岛素敏感性。这些患者的血浆骨化三醇浓度低于正常水平,同时完整甲状旁腺激素(PTH)浓度升高。因此,尚不清楚胰岛素敏感性的改善是由于骨化三醇的直接作用还是继发性甲状旁腺功能亢进的改善。到目前为止,尚无证据表明健康受试者的胰岛素敏感性受到骨化三醇的特异性影响。我们研究了(超)治疗剂量的骨化三醇对健康志愿者胰岛素敏感性的影响。在双盲平行组设计中,18名健康男性受试者按随机顺序口服安慰剂或每天1.5微克骨化三醇,持续7天。使用正常血糖钳夹技术评估胰岛素介导的葡萄糖摄取,即胰岛素敏感性。平均葡萄糖处置率,即M值,不受安慰剂或骨化三醇治疗的显著影响(安慰剂组:治疗前7.1±1.3mg·kg⁻¹·min⁻¹,治疗后7.2±1.5mg·kg⁻¹·min⁻¹;骨化三醇组:7.0±1.4mg·kg⁻¹·min⁻¹和7.2±1.4mg·kg⁻¹·min⁻¹)。给予安慰剂或骨化三醇后,平均血浆葡萄糖、胰岛素、磷酸盐、碳酸氢盐和离子钙浓度均无显著变化。此外,血小板细胞内钙浓度(通过荧光光谱法评估)和平均动脉血压(24小时动态测量)在安慰剂和骨化三醇治疗后均未改变。另一方面,骨化三醇治疗后平均完整PTH浓度显著降低(P<0.01),而安慰剂治疗则无此变化。此外,给予骨化三醇后平均24小时尿钙排泄显著增加(P<0.05),而安慰剂组则无变化。给予(超)生理剂量的骨化三醇对健康受试者的胰岛素敏感性无影响,尽管PTH浓度显著降低。这些观察结果与以下观点一致,即骨化三醇对胰岛素敏感性的影响仅存在于尿毒症性骨化三醇缺乏的患者中。